The crosstalk between DNA damage response and IDH1 mutation in the context of TP53 and ATRX loss indicated that IDH1 R132H acts as a tumor suppressor in glioma by epigenetically upregulating the ATM signaling pathway in mouse model and patient-derived xenograft model [52]. This evidence concerns the gene IDH1 and neoplasm.